Univar Solutions scientists developed a lidocaine cream built on starch, sorbitol, coconut oil, and beeswax that matched a commercial benchmark on viscosity, assay, and hydration.
|Articles|October 13, 2015
Stiplastics Unveils New Dosing Spoon at CPhI
Spoonbox is now available in a 13-mL format for dosing products in liquid form and micro-granules.
Advertisement
Stiplastics, a company specializing in the design and development of innovative injected plastic-based medical devices, has unveiled a new 13-mL Spoonbox dosing spoon at CPhI Worldwide 2015. According to Stiplastics, the new dosing spoon was developed in response to pharmaceutical laboratories requesting a device that has greater capacity than that of the 8-mL and 9-mL versions.
The Spoonbox product offers an alternative to the pipette in terms of economics, hygiene, and ergonomics. Quality and reliability are attributes of the product, says the company, along with the decorative options, which include pad-printing, to bring an element of fun to the task of taking medication, particularly where children are concerned.
Stiplastics has carried out validation work, which means that Spoonbox can also be used to measure micro-granules. Laboratory Lucane Pharma, for example, has chosen it for a micro-granule product designed to treat a rare disease.
Source: Stiplastics, 4C110
Advertisement
Related to this article
Nate Edwards of Arya Consulting moderates a discussion with Elisabeth Gardiner of Tevard Biosciences and Donny Xu of the RTW Institute about the regulatory and manufacturing hurdles facing rare disease drug developers.
FDA grants ravulizumab accelerated approval in IgA nephropathy after a 43.4% proteinuria cut, signaling new IV biologic demand for drug manufacturers.
Jane Zhang of ETCH Sourcing explains why geopolitics, transparency, and partnership now weigh as heavily as cost and quality when companies choose suppliers, in this episode of Ask the Expert, moderated by Susan J. Schniepp of Nelson Labs.
FDA approves GSK's bepirovirsen for chronic hepatitis B after a 19% functional cure rate, raising oligonucleotide scale-up stakes for manufacturers.
Ravi Kiran Kaja, PhD, USP, explains what harmonization of extractables and leachables standards looks like in practice.
Jaenisch, Muraru, and Pandey discuss new skills for QC and regulatory teams, plus patient trust, as new approach methodologies reshape pharma.
Nine duloxetine recalls since 2024 show why generic drug manufacturers need route-level nitrosamine risk assessment, not end-product testing alone.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Nitrosamine Problems and Industry Solutions: PharmTech Explained
2
Formulation and Evaluation of a Sustainable Analgesic Cream Utilizing Renewable Bio-Based Ingredients and Green Chemistry Design Principles
3
AAPS PharmSci 360 2026: System Suitability Standards in E&L Testing
4
OpenAI Bets on Accelerating Drug Development Timelines With Orchestra Bio
5